Daniel J George


Ontology type: schema:Person     


Person Info

NAME

Daniel J

SURNAME

George

Publications in SciGraph latest 50 shown

  • 2022-07-15 Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2022-04-17 Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types in ADVANCES IN THERAPY
  • 2022-03-15 A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2022-03-10 A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND) in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2022-02-21 Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study) in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2022-01-20 Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer in ONCOGENE
  • 2022-01-17 Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2022-01-03 The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC in NEOADJUVANT IMMUNOTHERAPY TREATMENT OF LOCALIZED GENITOURINARY CANCERS
  • 2021-11-03 Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2021-11-03 Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma in BIOMARKER RESEARCH
  • 2021-10-13 Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2021-09-15 Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma in BMC CANCER
  • 2021-09-02 Racial disparities in prostate cancer among black men: epidemiology and outcomes in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2021-08-07 Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma in BMC CANCER
  • 2021-04-05 Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment in NATURE MEDICINE
  • 2021-02-21 Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2021-02-18 Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer in BIOMARKER RESEARCH
  • 2020-10-28 Novel therapies are changing treatment paradigms in metastatic prostate cancer in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2020-07-23 Racial Disparity in Response to Prostate Cancer Systemic Therapies in CURRENT ONCOLOGY REPORTS
  • 2020-05-13 Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2020-02-28 Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone in ADVANCES IN THERAPY
  • 2019-12-20 The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-06-07 Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database in BMC CANCER
  • 2019-04-12 Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2019-01-21 A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2018-09-10 Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2018-02-13 Immune Checkpoint Blockade: The New Frontier in Cancer Treatment in TARGETED ONCOLOGY
  • 2018-01-29 Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2018-01-25 Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2017-12-11 Platinum sensitivity in metastatic prostate cancer: does histology matter? in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2017-02-25 Phase I study of pazopanib plus TH-302 in advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-02-02 Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2016-01-12 A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2015-05-07 Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report in BMC CANCER
  • 2015-02-04 A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-09-06 The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-08-14 Use of “Real-World” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice in MEDICAL ONCOLOGY
  • 2014-07-21 Angiogenesis Inhibition in Castration-Resistant Prostate Cancer in MANAGEMENT OF CASTRATION RESISTANT PROSTATE CANCER
  • 2014-03-12 Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-06-14 Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2010-01-12 Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2009 The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies in RENAL CELL CARCINOMA
  • 2007-01-01 Intercellular Targets of Prostate Cancer in PROSTATE CANCER
  • 2006-08-01 Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2006-04-01 Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement in EUROPEAN RADIOLOGY
  • 2004 Opportunities for Targeted Molecular Therapy for Prostate Cancer in MANAGEMENT OF PROSTATE CANCER
  • 2003 Targeting PDGF Receptors in Cancer ­ Rationales and Proof of Concept Clinical Trials in NEW TRENDS IN CANCER FOR THE 21STCENTURY
  • 1995-09 Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate in NATURE MEDICINE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.26009.3d", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.62560.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.239578.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.249335.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.152326.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.1055.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5802.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.15276.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5288.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14003.36", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413334.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.32224.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417587.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.25879.31", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.63984.30", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6279.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.170205.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.492639.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.476933.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412100.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410332.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5386.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.38142.3c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.21107.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.214458.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.65499.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410513.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.278247.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.9027.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.266102.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.17063.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410711.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.189509.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.239585.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.239395.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413734.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.468219.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414179.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6906.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.25073.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.464692.b", 
            "type": "Organization"
          }
        ], 
        "familyName": "George", 
        "givenName": "Daniel J", 
        "id": "sg:person.013110637342.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013110637342.47"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-08-04T17:38", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/person/person_871.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.013110637342.47'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.013110637342.47'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.013110637342.47'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.013110637342.47'


     

    This table displays all metadata directly associated to this object as RDF triples.

    104 TRIPLES      10 PREDICATES      55 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.013110637342.47 schema:affiliation N85cc427b62d444e3b268b530205924ab
    2 grid-institutes:grid.1055.1
    3 grid-institutes:grid.14003.36
    4 grid-institutes:grid.152326.1
    5 grid-institutes:grid.15276.37
    6 grid-institutes:grid.170205.1
    7 grid-institutes:grid.17063.33
    8 grid-institutes:grid.189509.c
    9 grid-institutes:grid.19006.3e
    10 grid-institutes:grid.21107.35
    11 grid-institutes:grid.214458.e
    12 grid-institutes:grid.239395.7
    13 grid-institutes:grid.239578.2
    14 grid-institutes:grid.239585.0
    15 grid-institutes:grid.240145.6
    16 grid-institutes:grid.249335.a
    17 grid-institutes:grid.25073.33
    18 grid-institutes:grid.25879.31
    19 grid-institutes:grid.266102.1
    20 grid-institutes:grid.278247.c
    21 grid-institutes:grid.32224.35
    22 grid-institutes:grid.38142.3c
    23 grid-institutes:grid.410332.7
    24 grid-institutes:grid.410513.2
    25 grid-institutes:grid.410711.2
    26 grid-institutes:grid.412100.6
    27 grid-institutes:grid.413334.2
    28 grid-institutes:grid.413734.6
    29 grid-institutes:grid.414179.e
    30 grid-institutes:grid.417587.8
    31 grid-institutes:grid.424926.f
    32 grid-institutes:grid.464692.b
    33 grid-institutes:grid.468219.0
    34 grid-institutes:grid.476933.c
    35 grid-institutes:grid.492639.3
    36 grid-institutes:grid.51462.34
    37 grid-institutes:grid.5288.7
    38 grid-institutes:grid.5386.8
    39 grid-institutes:grid.5802.f
    40 grid-institutes:grid.62560.37
    41 grid-institutes:grid.6279.a
    42 grid-institutes:grid.63984.30
    43 grid-institutes:grid.65499.37
    44 grid-institutes:grid.6906.9
    45 grid-institutes:grid.9027.c
    46 schema:familyName George
    47 schema:givenName Daniel J
    48 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013110637342.47
    49 schema:sdDatePublished 2022-08-04T17:38
    50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    51 schema:sdPublisher N6807aa5941e547d78dfe157ca359c93f
    52 sgo:license sg:explorer/license/
    53 sgo:sdDataset persons
    54 rdf:type schema:Person
    55 N6807aa5941e547d78dfe157ca359c93f schema:name Springer Nature - SN SciGraph project
    56 rdf:type schema:Organization
    57 N85cc427b62d444e3b268b530205924ab schema:affiliation grid-institutes:grid.26009.3d
    58 sgo:isCurrent true
    59 rdf:type schema:OrganizationRole
    60 grid-institutes:grid.1055.1 schema:Organization
    61 grid-institutes:grid.14003.36 schema:Organization
    62 grid-institutes:grid.152326.1 schema:Organization
    63 grid-institutes:grid.15276.37 schema:Organization
    64 grid-institutes:grid.170205.1 schema:Organization
    65 grid-institutes:grid.17063.33 schema:Organization
    66 grid-institutes:grid.189509.c schema:Organization
    67 grid-institutes:grid.19006.3e schema:Organization
    68 grid-institutes:grid.21107.35 schema:Organization
    69 grid-institutes:grid.214458.e schema:Organization
    70 grid-institutes:grid.239395.7 schema:Organization
    71 grid-institutes:grid.239578.2 schema:Organization
    72 grid-institutes:grid.239585.0 schema:Organization
    73 grid-institutes:grid.240145.6 schema:Organization
    74 grid-institutes:grid.249335.a schema:Organization
    75 grid-institutes:grid.25073.33 schema:Organization
    76 grid-institutes:grid.25879.31 schema:Organization
    77 grid-institutes:grid.26009.3d schema:Organization
    78 grid-institutes:grid.266102.1 schema:Organization
    79 grid-institutes:grid.278247.c schema:Organization
    80 grid-institutes:grid.32224.35 schema:Organization
    81 grid-institutes:grid.38142.3c schema:Organization
    82 grid-institutes:grid.410332.7 schema:Organization
    83 grid-institutes:grid.410513.2 schema:Organization
    84 grid-institutes:grid.410711.2 schema:Organization
    85 grid-institutes:grid.412100.6 schema:Organization
    86 grid-institutes:grid.413334.2 schema:Organization
    87 grid-institutes:grid.413734.6 schema:Organization
    88 grid-institutes:grid.414179.e schema:Organization
    89 grid-institutes:grid.417587.8 schema:Organization
    90 grid-institutes:grid.424926.f schema:Organization
    91 grid-institutes:grid.464692.b schema:Organization
    92 grid-institutes:grid.468219.0 schema:Organization
    93 grid-institutes:grid.476933.c schema:Organization
    94 grid-institutes:grid.492639.3 schema:Organization
    95 grid-institutes:grid.51462.34 schema:Organization
    96 grid-institutes:grid.5288.7 schema:Organization
    97 grid-institutes:grid.5386.8 schema:Organization
    98 grid-institutes:grid.5802.f schema:Organization
    99 grid-institutes:grid.62560.37 schema:Organization
    100 grid-institutes:grid.6279.a schema:Organization
    101 grid-institutes:grid.63984.30 schema:Organization
    102 grid-institutes:grid.65499.37 schema:Organization
    103 grid-institutes:grid.6906.9 schema:Organization
    104 grid-institutes:grid.9027.c schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...